Bio Protocol has secured $6.9 million in seed funding to enhance decentralized science (DeSci) and biotechnology through AI and blockchain. The funding round was led by Arthur Hayes' Maelstrom Fund, with participation from Animoca Brands. CEO Paul Kohlhaas aims to democratize scientific research funding, making it more accessible to independent scientists. The initiative, supported by industry leaders like Hayes and Kohlhaas, seeks to integrate AI into drug research, challenging traditional pharmaceutical structures. This move is expected to foster innovation within the DeSci community and impact the BIO token market.